Infection Spectrum Test

About Attomarker

Attomarker is a private, commercial-stage diagnostics company founded in 2016 as a spin-out from the University of Exeter. It has developed a proprietary multiplex diagnostic platform that uses gold nanoparticle nanotechnology and microfluidics to provide quantitative, multi-biomarker results in approximately seven minutes. The company is currently generating early revenue from its first authorized test for Long COVID immune profiling and is actively fundraising to scale its platform and expand its test pipeline into areas like Lyme disease, fertility, and liver health.

Therapeutic Areas